Insights

Innovative Drug Delivery Technology Halozyme is a biopharmaceutical company known for its innovative ENHANZE technology, which revolutionizes drug delivery, reducing treatment times significantly. This technology has been commercialized in multiple products across global markets, positively impacting over 400,000 patient lives. This unique selling point can be leveraged to attract potential partners and clients seeking more efficient drug delivery solutions.

Strategic Pharmaceutical Partnerships Halozyme has established partnerships with leading pharmaceutical companies including Roche, Pfizer, and AbbVie, licensing its ENHANZE technology to facilitate drug development. These collaborations not only generate revenues for Halozyme through milestones and royalties but also present opportunities for sales professionals to engage with these prominent players in the industry, potentially leading to new business opportunities and expanding the company's market reach.

Growing Investment Interest Recent investments from notable firms like Heck Capital Advisors, Outlook Wealth Advisors, and CDPQ indicate growing interest in Halozyme's potential and future prospects. These investments signal confidence in the company's innovative solutions, presenting an opportunity for sales development representatives to tap into this positive market sentiment and capitalize on the heightened investor attention to drive business growth.

Expansion Through Strategic Acquisitions The integration with Evotec SE showcases Halozyme's strategic approach to expanding its capabilities by combining drug delivery technology with drug discovery platforms. This move not only enhances Halozyme's offerings but also presents sales professionals with potential collaboration opportunities, access to new markets, and the chance to position the company as a key player in the evolving biopharmaceutical landscape.

Investment Potential and Financial Health With revenues estimated between $50M - $100M and a funding of $500M, Halozyme demonstrates financial stability and growth potential. This information can be utilized by sales professionals to instill confidence in potential partners, investors, and clients regarding the company's financial health and sustainable growth trajectory, offering a solid foundation for future sales engagements and business development strategies.

Similar companies to Halozyme, Inc.

Halozyme, Inc. Tech Stack

Halozyme, Inc. uses 8 technology products and services including Salesforce, Google Font API, Microsoft, and more. Explore Halozyme, Inc.'s tech stack below.

  • Salesforce
    Customer Relationship Management
  • Google Font API
    Font Scripts
  • Microsoft
    Miscellaneous
  • Microsoft Word
    Office Suites
  • Yammer
    Team Collaboration
  • Bootstrap
    UI Frameworks
  • VMware
    Virtualisation Software
  • Apache HTTP Server
    Web Servers

Media & News

Halozyme, Inc.'s Email Address Formats

Halozyme, Inc. uses at least 1 format(s):
Halozyme, Inc. Email FormatsExamplePercentage
FLast@halozyme.comJDoe@halozyme.com
90%
First.Last@halozyme.comJohn.Doe@halozyme.com
5%
Last@halozyme.comDoe@halozyme.com
4%
LFirst@halozyme.comDJohn@halozyme.com
1%

Frequently Asked Questions

Where is Halozyme, Inc.'s headquarters located?

Minus sign iconPlus sign icon
Halozyme, Inc.'s main headquarters is located at 12390 El Camino Real San Diego, California 92130 US. The company has employees across 6 continents, including North AmericaAsiaEurope.

What is Halozyme, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact Halozyme, Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Halozyme, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Halozyme, Inc.'s official website is halozyme.com and has social profiles on LinkedIn.

How much revenue does Halozyme, Inc. generate?

Minus sign iconPlus sign icon
As of January 2025, Halozyme, Inc.'s annual revenue reached $75M.

What is Halozyme, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
Halozyme, Inc.'s SIC code is 2834 - Pharmaceutical Preparations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Halozyme, Inc. have currently?

Minus sign iconPlus sign icon
As of January 2025, Halozyme, Inc. has approximately 461 employees across 6 continents, including North AmericaAsiaEurope. Key team members include CEO: H. T.CFO: P. N.Chief Information Officer: L. B.. Explore Halozyme, Inc.'s employee directory with LeadIQ.

What industry does Halozyme, Inc. belong to?

Minus sign iconPlus sign icon
Halozyme, Inc. operates in the Biotechnology Research industry.

What technology does Halozyme, Inc. use?

Minus sign iconPlus sign icon
Halozyme, Inc.'s tech stack includes SalesforceGoogle Font APIMicrosoftMicrosoft WordYammerBootstrapVMwareApache HTTP Server.

What is Halozyme, Inc.'s email format?

Minus sign iconPlus sign icon
Halozyme, Inc.'s email format typically follows the pattern of . Find more Halozyme, Inc. email formats with LeadIQ.

How much funding has Halozyme, Inc. raised to date?

Minus sign iconPlus sign icon
As of January 2025, Halozyme, Inc. has raised $500M in funding. The last funding round occurred on Aug 15, 2022 for $500M.
Halozyme, Inc.

Halozyme, Inc.

Biotechnology ResearchCalifornia, United States201-500 Employees

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme's commercially-validated solution has positively impacted more than 400,000 patient lives via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the company's partners make progress developing and commercializing their products being developed with ENHANZE®. 

We are a diverse team, who are committed to bringing therapies and results to patients. It's not enough to be qualified and experienced at what you do, we are looking for people who believe in our mission and match our values. 

We are building a company where people can pursue their career goals in a supportive and collaborative team environment. Visit www.halozyme.com/careers for more details.   

We are Halozyme.

Section iconCompany Overview

Headquarters
12390 El Camino Real San Diego, California 92130 US
Phone number
SIC Code
2834 - Pharmaceutical Preparations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
201-500

Section iconFunding & Financials

  • $500M

    Halozyme, Inc. has raised a total of $500M of funding over 7 rounds. Their latest funding round was raised on Aug 15, 2022 in the amount of $500M.

  • $50M$100M

    Halozyme, Inc.'s revenue is in the range of $50M$100M

Section iconFunding & Financials

  • $500M

    Halozyme, Inc. has raised a total of $500M of funding over 7 rounds. Their latest funding round was raised on Aug 15, 2022 in the amount of $500M.

  • $50M$100M

    Halozyme, Inc.'s revenue is in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.